Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director

Medical doctor experienced in psychedelic assisted therapy and research to help advance Numinus protocol development and safe delivery of company’s patient-focused model

VANCOUVER (June 3, 2020)—Dr. Evan Wood, Numinus Chief Medical Officer, today announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX-V: NUMI) — another key step in the Company’s evolution as a leader in the advancement of psychedelic therapies, treatment and research.

“We are embarking on an exciting journey at Numinus,” Dr. Wood says. “We are working with health authorities, regulators and Colleges to advance research and protocol development to explore the application of psychedelic assisted psychotherapies in safe, controlled therapeutic environments. Devon will play a key role in the Company in helping to design and implement our patient-focused model for when we are able to put these therapies in place.”

Dr. Christie, a clinical instructor with the UBC Department of Medicine, is also a family physician with a focused practice in Multidisciplinary Pain Management. She is a Registered Therapeutic Counsellor emphasizing Relational Somatic Therapy for trauma resolution and she is also trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy, in a research setting. She is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.

“As a medical doctor, I have always been interested in non-traditional approaches to therapy and treatment,” Dr. Christie says. “My unique and diverse clinical background, combined with rich personal experience helps me better understand and synthesize healing across disciplines — something Numinus is on a mission to achieve.”

In her role as Numinus’s Medical Director, she will lead a working group and advisory team for the purpose of protocol development and establishing a standard of excellence and professionalism in the safe and ethical delivery of Numinus’s new therapies; provide input on the organizational structure and lead the hiring of key clinical staff and contractors to establish the clinical team for the safe delivery of Numinus' therapies (when psychedelic therapies are approved for use by regulators); and, as plans are developed to establish Numinus clinical sites, assist in the planning and establishment of physical infrastructure and clinic procedures required for delivering Numinus' services.

- 30 -

Contact:

Investor Inquiries:

invest@numinus.ca

Media Inquiries:

Emily Edwards, NATIONAL

eedwards@national.ca

604-842-6490

General Inquiries:

hello@numinus.ca

1-833-NUM-INUS (1-833-686-4687)

Pour investir et obtenir des renseignements généraux en français:

Remy Scalabrini, Maricom

investir@numinus.ca

888-585-6274

About Numinus

Numinus is a Vancouver-based health care company helping to support the universal desire to heal and be well. Through its wholly-owned subsidiary Salvation Botanicals, Numinus has a Health Canada cannabis testing licence that allows the company to test and analyze cannabis products from licensed producers. In addition, it is a late-stage applicant to receive a Health Canada standard processing licence to produce cannabis products. Numinus, through the same subsidiary, also has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. It is seeking to expand the licence to include activities such as import/export, testing and R&D. The expanded licence will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus Wellness is dedicated to therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. Psychedelics will be part of this offering but will only be available for treatment once approved by regulators and governing bodies — a process Numinus is helping to support. For more information, visit www.numinus.ca.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.